156 related articles for article (PubMed ID: 38660141)
1. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness.
Shirali AS; Hu MI; Chiang YJ; Graham PH; Fisher SB; Sosa JA; Perrier N; Brown S; Holla VR; Dadu R; Busaidy N; Sherman SI; Cabanillas M; Waguespack SG; Zafereo ME; Grubbs EG
J Endocr Soc; 2024 Apr; 8(6):bvae048. PubMed ID: 38660141
[TBL] [Abstract][Full Text] [Related]
2. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
[No Abstract] [Full Text] [Related]
3. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
4. A cohort study on 10-year survival of sporadic medullary thyroid carcinoma with somatic RET mutation.
Chuang LL; Hwang DY; Tsai KB; Chan HM; Chiang FY; Hsiao PJ
Kaohsiung J Med Sci; 2016 Nov; 32(11):545-551. PubMed ID: 27847096
[TBL] [Abstract][Full Text] [Related]
5. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
[No Abstract] [Full Text] [Related]
6. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
[TBL] [Abstract][Full Text] [Related]
7. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.
Ciampi R; Romei C; Ramone T; Prete A; Tacito A; Cappagli V; Bottici V; Viola D; Torregrossa L; Ugolini C; Basolo F; Elisei R
iScience; 2019 Oct; 20():324-336. PubMed ID: 31605946
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
10. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
[TBL] [Abstract][Full Text] [Related]
11. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double
Romei C; Casella F; Tacito A; Bottici V; Valerio L; Viola D; Cappagli V; Matrone A; Ciampi R; Piaggi P; Ugolini C; Torregrossa L; Basolo F; Materazzi G; Vitti P; Elisei R
J Med Genet; 2016 Nov; 53(11):729-734. PubMed ID: 27468888
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
Hensley SG; Hu MI; Bassett RL; Ying AK; Zafereo ME; Perrier ND; Busaidy NL; Hyde SM; Grubbs EG; Waguespack SG
J Clin Endocrinol Metab; 2024 Mar; ():. PubMed ID: 38441533
[TBL] [Abstract][Full Text] [Related]
14. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
15. Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma.
Raue F; Bruckner T; Frank-Raue K
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3582-e3591. PubMed ID: 33974051
[TBL] [Abstract][Full Text] [Related]
16. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
17. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
18. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
[TBL] [Abstract][Full Text] [Related]
19. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]